Roche, hoping to move on from recent failure, pens $190M NeuExcell Huntington's disease pact

Roche, like so many others in the field, has seen major setbacks in trying to hunt new drugs for Huntington’s disease, but it’s brushing off a recent flop and signing up with a new partner in the hopes of trying again.